scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.PRP.2010.08.005 |
P698 | PubMed publication ID | 21095069 |
P50 | author | Yi-Long Wu | Q42663698 |
P2093 | author name string | Li Li | |
Meng Yao | |||
Ning Liao | |||
Guo-chun Zhang | |||
Yan-hui Liu | |||
Fang-ping Xu | |||
Xue-rui Li | |||
P433 | issue | 1 | |
P921 | main subject | ductal carcinoma | Q5311598 |
P304 | page(s) | 1-7 | |
P577 | publication date | 2010-11-20 | |
P1433 | published in | Pathology, Research and Practice | Q15758752 |
P1476 | title | HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component | |
P478 | volume | 207 |
Q35735366 | Aldehyde dehydrogenase 1 expression correlates with the invasion of breast cancer |
Q36897778 | Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer |
Q38648122 | Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ |
Q51145791 | Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status. |
Q38250760 | Ductal carcinoma in situ with distorting sclerosis on core biopsy may be predictive of upstaging on excision |
Q38429498 | Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer |
Q39218576 | Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression |
Q49061414 | Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. |
Q46057336 | Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast |
Q36449263 | Potential use of vaccines in the primary prevention of breast cancer in high-risk patients |
Q54513997 | Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. |
Q52920490 | Preoperatively diagnosed ductal carcinoma in situ: risk prediction of invasion and effects on axillary management. |
Q50592584 | Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. |
Q40588935 | Sonographic Features of Ductal Carcinoma In Situ of the Breast With Microinvasion: Correlation With Clinicopathologic Findings and Biomarkers |
Q35660389 | The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study |
Q35201328 | The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease |
Q90394997 | Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile |